{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:06:52Z","timestamp":1786216012632,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873446"],"award-info":[{"award-number":["81873446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012164","name":"National High-tech Research and Development Program","doi-asserted-by":"publisher","award":["2021YFA1101504"],"award-info":[{"award-number":["2021YFA1101504"]}],"id":[{"id":"10.13039\/501100012164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101078","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T18:23:20Z","timestamp":1680200600000},"page":"101078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification"],"prefix":"10.1016","volume":"62","author":[{"given":"Yun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.blre.2023.101078_bb0005","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","article-title":"Allogeneic stem cell transplantation: a historical and scientific overview","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res"},{"issue":"26","key":"10.1016\/j.blre.2023.101078_bb0010","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2023.101078_bb0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101078_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.blre.2023.101078_bb0030","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood."},{"issue":"31","key":"10.1016\/j.blre.2023.101078_bb0035","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.blre.2023.101078_bb0040","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41409-019-0547-8","article-title":"Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application","volume":"55","author":"El Fakih","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.blre.2023.101078_bb0050","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101078_bb0055","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","article-title":"Granulocyte Colony-stimulating factor-primed Unmanipulated Haploidentical blood and marrow transplantation","volume":"10","author":"Chang","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11684-017-0595-7","article-title":"Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation","volume":"13","author":"Lv","year":"2019","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101078_bb0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101078_bb0070","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.blre.2023.101078_bb0075","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4049\/jimmunol.145.5.1303","article-title":"Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion","volume":"145","author":"Eto","year":"1990","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.blre.2023.101078_bb0080","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/eji.1830200919","article-title":"The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance","volume":"20","author":"Eto","year":"1990","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.171.1.97","article-title":"Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens","volume":"171","author":"Eto","year":"1990","journal-title":"J Exp Med"},{"issue":"211","key":"10.1016\/j.blre.2023.101078_bb0090","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.blre.2023.101078_bb0095","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00007890-198510000-00019","article-title":"Drug-induced tolerance to allografts in mice. VIII. Effects of thymectomy and\/or splenectomy on tolerance induction in an H-2-haplotype-identical strain combination","volume":"40","author":"Mayumi","year":"1985","journal-title":"Transplantation."},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0105","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101078_bb0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/bmt.2015.270","article-title":"T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes","volume":"51","author":"Devillier","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101078_bb0125","doi-asserted-by":"crossref","first-page":"928.e1","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A phase I\/II multicenter trial of HLA-Haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0130","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia","volume":"106","author":"Nagler","year":"2021","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0140","doi-asserted-by":"crossref","first-page":"204.e1","DOI":"10.1016\/j.jtct.2022.01.020","article-title":"Post-transplantation cyclophosphamide after HLA identical compared to Haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC","volume":"28","author":"Bailen","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.blre.2023.101078_bb0145","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bbmt.2015.01.026","article-title":"Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity Busulfan\/Fludarabine conditioning for hematological malignancies","volume":"21","author":"Alousi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ejh.12541","article-title":"OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0155","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate Mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","article-title":"Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation","volume":"54","author":"Shah","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101078_bb0165","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101078_bb0170","doi-asserted-by":"crossref","first-page":"500.e1","DOI":"10.1016\/j.jtct.2022.05.039","article-title":"Mycophenolate Mofetil: a friend or a foe with post-transplantation cyclophosphamide and tacrolimus prophylaxis in HLA-matched donors?","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.blre.2023.101078_bb0175","doi-asserted-by":"crossref","first-page":"619.e1","DOI":"10.1016\/j.jtct.2021.03.022","article-title":"High-dose cyclophosphamide and tacrolimus as graft-versus-host disease prophylaxis for matched and mismatched unrelated donor transplantation","volume":"27","author":"Pedraza","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.blre.2023.101078_bb0180","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.13977","article-title":"Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation","volume":"173","author":"Mehta","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0185","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2023.101078_bb0190","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","article-title":"Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome","volume":"27","author":"Modi","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.blre.2023.101078_bb0195","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/bloodadvances.2022007596","article-title":"Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant","volume":"6","author":"Jimenez Jimenez","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.blre.2023.101078_bb0200","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101078_bb0205","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41375-020-0863-4","article-title":"Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9\/10 or 10\/10 HLA-matched unrelated donors for acute leukemia","volume":"35","author":"Lorentino","year":"2021","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0210","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MOH.0b013e3283582322","article-title":"Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts","volume":"19","author":"Chang","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"26","key":"10.1016\/j.blre.2023.101078_bb0215","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101078_bb0220","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41409-020-0897-2","volume":"55","author":"ElGohary","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbmt.2015.11.001","article-title":"Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States","volume":"22","author":"Apperley","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101078_bb0230","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology."},{"issue":"5","key":"10.1016\/j.blre.2023.101078_bb0235","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4049\/jimmunol.2000578","article-title":"Posttransplant cyclophosphamide and antithymocyte globulin versus Posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution","volume":"205","author":"Makanga","year":"2020","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0240","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ejh.13230","article-title":"Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants","volume":"102","author":"Prem","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101078_bb0245","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41409-018-0382-3","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0250","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00277-020-04033-2","article-title":"Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation","volume":"99","author":"Pasic","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101078_bb0260","doi-asserted-by":"crossref","first-page":"587.e1","DOI":"10.1016\/j.jtct.2022.06.006","volume":"28","author":"Battipaglia","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.blre.2023.101078_bb0265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0270","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12185-021-03280-x","article-title":"Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies","volume":"115","author":"Chen","year":"2022","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101078_bb0275","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41409-022-01816-1","article-title":"Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"57","author":"Spyridonidis","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101078_bb0280","doi-asserted-by":"crossref","first-page":"396.e1","DOI":"10.1016\/j.jtct.2022.04.021","article-title":"Comparisons of modified post-transplantation cyclophosphamide and granulocyte colony-stimulating factor\/antithymocyte globulin regimens for haploidentical stem cell transplantation in patients with aplastic anemia","volume":"28","author":"Li","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0285","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41409-019-0725-8","article-title":"Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases","volume":"55","author":"Leick","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2023.101078_bb0290","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41409-020-0813-9","article-title":"Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD","volume":"55","author":"Salas","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0295","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000507536","article-title":"Post-transplant cyclophosphamide combined with anti-Thymocyte globulin as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"144","author":"Alanazi","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2023.101078_bb0300","article-title":"Sequential transplantation of Haploidentical stem cell and unrelated cord blood with using ATG\/PTCY increases survival of relapsed\/refractory hematologic malignancies","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.blre.2023.101078_bb0305","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41409-021-01302-0","article-title":"Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide","volume":"56","author":"Oostenbrink","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101078_bb0310","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41409-021-01358-y","article-title":"Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation","volume":"56","author":"Sun","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0315","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41409-019-0726-7","article-title":"Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies","volume":"55","author":"Peric","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101078_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106918","volume":"120","author":"Barkhordar","year":"2022","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.blre.2023.101078_bb0325","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","article-title":"A modified post-transplant cyclophosphamide regimen, for Unmanipulated Haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study","volume":"24","author":"Chiusolo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2023.101078_bb0330","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101078_bb0335","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide Administration in Haploidentical Transplantation: a comparative study on behalf of the acute leukemia working Party of the European Society for blood and marrow transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101078_bb0340","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101078_bb0345","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2021-146997","article-title":"Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation","volume":"138","author":"McAdams","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101078_bb0350","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1038\/s41598-021-92526-z","article-title":"Reduced dose of PTCy followed by adjuvant alpha-galactosylceramide enhances GVL effect without sacrificing GVHD suppression","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.blre.2023.101078_bb0355","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0360","doi-asserted-by":"crossref","first-page":"213.e1","DOI":"10.1016\/j.jtct.2022.01.011","article-title":"Risk of cytomegalovirus infection with post-transplantation cyclophosphamide in haploidentical and HLA-matched unrelated donor transplantation","volume":"28","author":"Jamy","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.blre.2023.101078_bb0365","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bmt.2010.213","article-title":"Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia","volume":"46","author":"Dezern","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101078_bb0370","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbmt.2017.10.034","article-title":"Post-transplant cyclophosphamide as sole graft-versus-host disease prophylaxis is feasible in patients undergoing peripheral blood stem cell transplantation for severe aplastic anemia using matched sibling donors","volume":"24","author":"George","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101078_bb0375","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","article-title":"Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia","volume":"20","author":"Clay","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101078_bb0380","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101078_bb0385","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101078_bb0390","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2023.101078_bb0395","doi-asserted-by":"crossref","first-page":"429 e1","DOI":"10.1016\/j.jtct.2021.02.014","article-title":"Haploidentical peripheral stem cell transplantation for young patients with severe aplastic anemia using post-transplantation cyclophosphamide and methotrexate","volume":"27","author":"Yang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101078_bb0400","first-page":"331.e31","article-title":"Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic Anemia: a multicenter experience","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.blre.2023.101078_bb0405","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","article-title":"Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders","volume":"22","author":"Klein","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101078_bb0410","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s10875-021-01113-4","article-title":"Haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide for children with non-malignant diseases","volume":"41","author":"Hashem","year":"2021","journal-title":"J Clin Immunol"},{"issue":"11","key":"10.1016\/j.blre.2023.101078_bb0415","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.bbmt.2019.07.010","article-title":"Successful outcome in patients with Fanconi anemia undergoing T cell-replete mismatched related donor hematopoietic cell transplantation using reduced-dose cyclophosphamide post-transplantation","volume":"25","author":"Ayas","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101078_bb0420","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children","volume":"25","author":"Neven","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101078_bb0425","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.bbmt.2020.07.003","article-title":"Outcomes after haploidentical stem cell transplantation with post-transplantation cyclophosphamide in patients with primary immunodeficiency diseases","volume":"26","author":"Fernandes","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101078_bb0430","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.bbmt.2020.08.019","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide in Fanconi anemia: improving outcomes with improved supportive care in India","volume":"26","author":"Uppuluri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101078_bb0435","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41409-020-01040-9","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases","volume":"56","author":"Even-Or","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101078_bb0440","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s10875-020-00898-0","article-title":"Reduced intensity bone marrow transplantation with post-transplant cyclophosphamide for pediatric inherited immune deficiencies and bone marrow failure syndromes","volume":"41","author":"Klein","year":"2021","journal-title":"J Clin Immunol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:56Z","timestamp":1759436936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":88,"alternative-id":["S0268960X23000395"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101078","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101078"}}